GABBR1 and metabolic disease: Preclinical and clinical studies have indicated that the binding of agonists or antagonists to GB1/2‐regulating sites in GABA promotes or suppresses food intake or disordered eating [64, 66, 86] in the nutrition and metabolism disorders.